Batten Disease is a genetic disorder which is caused by autosomal recessive genetic mutation mainly occur in the childhood. Batten disease is also considered as lysosome shortage disease. Symptom of batten diseases occur due to malfunctioning of the body and can be observed between the age of five and fifteen years but it takes a few years to show symptoms such as vision loss, behaviors changes resulting in blindness and Parkinson-like symptoms. FDA approve first cerliponase alfa first ever drug to treat a slow loss of walking ability. Till, there is no treatment but there are few tests for batten disease and can be diagnosed by some laboratory tests which include blood test, urine sample MRI and CT scan. According to the National Human Genome Research Institute (NHGRI), Juvenile batten is one of the common diseases affecting almost 30 million population. There are some clinical trials studies being carried out in the North America, Western Europe, and Asia Pacific which is expected to increase the demand for batten disease treatment.
Increased prevalence of disease and clinical trials are expected to spur the growth of batten disease treatment market. A number of physical therapies may be used to treat the batten disease such as stem-cell therapy, enzyme-replacement therapy and gene therapy are expected to increase the demand for batten disease treatment. In addition, there is also fetal stem cell material which may be possible to treat brain of affected children and this is anticipated to increase the growth of batten disease treatment market. Besides, receiving vitamin supplements also help affected children and resulted slowing of the batten disease which is expected to increase the growth of batten disease treatment market.
However, factors such as no specific treatment for batten disease treatment will hinder the growth of batten disease treatment market.
The global Batten Disease Treatment market is segmented on the basis of Disease type, Treatment and Geography:
Based on Disease type, Batten Disease Treatment Market is segmented into the following:
Based on Treatment type, Batten Disease Treatment Market is segmented into the following:
Batten disease treatment market is segmented into disease type and treatment type. As yet there is no specific treatment for batten disease but seizures can be reduced with anticonvulsant drugs, and also controlled by certain therapies to reduces medical problem. On the basis of disease type, Juvenile NCL is expected to increase the demand for batten disease treatment market. Juvenile NCL is a common disease which occur affect almost 1 out every 10 American. On the basis of treatment type, batten disease treatment is segmented into occupational therapies and physical therapies. For patients, these therapies are used to retain their functions but not prohibited the final result of the disease.
Geographically, the batten disease treatment market is segmented into regions such as Latin America, Europe, North America, South Asia, East Asia Middle East & Africa and Oceania. North America is projected to emerge as prominent market in the global Batten Disease treatment market due to increasing incidence of batten disease, increasing healthcare expenditure and presence of local manufactures. Further, Europe is the second regional market after north America which is expected t show significant growth in coming years. The growth is due to local manufactures and increased prevalence of batten disease. However, Asia-Pacific is expected to witness minimum growth due to lack of awareness among the manufactures and patient pool.
Some of the major key players competing in the global batten disease treatment market are Seneb BioSciences, Inc., ReGenX Biosciences LLC, BioMarin Pharmaceuticals, Ionis Pharmaceuticals, Inc., and Celenex and Inc. Manufacturers are participating for the development of effective and new drugs for the treatment of batten disease are expected to surge the growth of batten disease treatment market.
The report covers exhaustive analysis on:
Regional analysis includes